KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation.
Jackson
William F
WF
D000818:Animals; D002465:Cell Movement; D049109:Cell Proliferation / Q000187:drug effects; D005838:Genotype; D006801:Humans; D006965:Hyperplasia; D051664:Kv1.3 Potassium Channel / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D026902:Potassium Channel Blockers / Q000627:therapeutic use; D051637:Shaker Superfamily of Potassium Channels / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation; D014652:Vascular Diseases / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology
C496974:Kcna3 protein, mouse; C101328:Kcnab2 protein, mouse; D051664:Kv1.3 Potassium Channel; D026902:Potassium Channel Blockers; D051637:Shaker Superfamily of Potassium Channels